Asset Entities Inc Shares Down, Options Activity Moderate
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6d ago
0mins
Should l Buy ASST?
Moderately bullish activity in Asset Entities Inc (ASST), with shares down 9c near $0.73. Options volume relatively light with 81k contracts traded and calls leading puts for a put/call ratio of 0.08, compared to a typical level near 0.08. Implied volatility (IV30) is higher by 9.8 points near 129.11,in the bottom quartile of the past year, suggesting an expected daily move of $0.06. Put-call skew flattened, suggesting a modestly bullish tone.Looking ahead: Asset Entities Inc (ASST) will report earnings after the close on 2026-02-09.Option markets are pricing in a 50% probability of a move greater than 27.88% or $0.20.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ASST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ASST
Wall Street analysts forecast ASST stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASST is 1.50 USD with a low forecast of 1.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 11.915
Low
1.50
Averages
1.50
High
1.50
Current: 11.915
Low
1.50
Averages
1.50
High
1.50
About ASST
Strive, Inc., formerly Asset Entities Inc., is an asset management Bitcoin treasury company. The Company is focused on increasing Bitcoin per share to outperform Bitcoin over the long run. The Company's subsidiary, Strive Asset Management, LLC, is an SEC-registered investment adviser, which has assets under management (AUM) across approximately 13 exchange-traded funds, collective investment trusts, and a direct indexing platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Strategy Reports Q4 Revenue Beat, Stock Futures Lower
- Revenue Beat: Strategy reported fourth-quarter revenue of $122.99 million after Thursday's close, surpassing analyst expectations of $118.48 million, indicating strong market performance that may attract more investor interest.
- Earnings Growth: The company posted adjusted earnings of $16.37 per share, exceeding analyst estimates of $10.96 per share, demonstrating significant improvement in profitability that could lay the groundwork for future growth.
- Stock Price Decline: Despite the revenue and earnings beats, Strategy's stock dipped 4.8% to $128.36 in pre-market trading, reflecting market concerns about the overall economic environment, which may impact investor confidence.
- Market Trends: U.S. stock futures were lower, with Nasdaq 100 futures falling around 100 points, indicating cautious market sentiment that could pressure tech stocks and influence overall investment strategies.
See More
Strive (ASST) Prices 1.32M Shares of Series A Preferred Stock at $90 Each
- Preferred Stock Offering: Strive announced the pricing of 1.32 million shares of its variable rate Series A perpetual preferred stock at $90 per share, providing significant funding support and enhancing its capital structure.
- Follow-On Offering Plans: The company plans a $150 million follow-on offering, reflecting a proactive response to market demand and aiding in the expansion of its capital base for future growth.
- Settlement Arrangement: The preferred stock offering is scheduled to settle on January 27, 2026, indicating the company's active engagement in capital markets and strategic planning for future financing.
- Convertible Note Exchange: Strive also intends to enter into privately negotiated exchange agreements with Semler convertible note holders for $90 million, expected to result in the issuance of approximately 930,000 new shares of SATA stock, further optimizing its capital structure.
See More
Strive (SATA) Plans $150 Million Follow-On Offering of Preferred Stock
- Offering Plan: Strive (SATA) plans a $150 million follow-on offering of its Variable Rate Series A Perpetual Preferred Stock, with implementation contingent on market conditions, aimed at optimizing its capital structure and enhancing financial flexibility.
- Use of Proceeds: The net proceeds from this offering will be used alongside cash on hand to repay or repurchase outstanding convertible notes and other borrowings at its wholly owned subsidiary Semler Scientific, as well as for bitcoin-related investments, working capital, and general corporate purposes, indicating the company's focus on diversified investments.
- Debt Restructuring Negotiations: Strive is also negotiating potential exchanges of some outstanding convertible notes for preferred shares, which could reduce the offering size, although such exchanges would not generate cash proceeds, reflecting the company's flexible strategy in optimizing its capital structure.
- Market Reaction: Following the announcement of the offering, Strive's stock price fell 2.74% in after-hours trading to $0.8679, indicating a cautious market response to the offering plan, which may impact investor confidence.
See More
Strive, Inc. Completes Semler Acquisition, Stock Declines
- Bitcoin Holdings: Strive currently holds approximately 12,797.9 bitcoins, making it the 11th largest publicly traded corporate holder globally, indicating a strategic positioning in the cryptocurrency sector.
- Executive Appointment: Avik Roy has been appointed as Chief Strategy Officer, focusing on monetizing Semler Scientific's operations by expanding into early-disease detection products, aiming to enhance the company's competitiveness in the healthcare industry.
- Stock Performance: Strive's stock is trading at $0.96, which is 5.2% above its 20-day simple moving average but 56.4% below its 100-day simple moving average, reflecting a struggle to maintain long-term momentum.
- Earnings Expectations: Analysts expect Strive to report an EPS of -$0.01 on March 30, 2026, an improvement from -$0.21 year-over-year, with projected revenue of $1.80 million, indicating potential for future growth.
See More
Strive, Inc. Completes Semler Scientific Acquisition, Holds 12,797.9 Bitcoin
- Bitcoin Holdings Increase: Following the acquisition of Semler Scientific, Strive now holds approximately 12,797.9 bitcoins, making it the 11th largest public corporate holder globally, thereby enhancing its market position in the digital asset space.
- Strategic Executive Appointment: Avik Roy has been appointed as Chief Strategy Officer, focusing on monetizing the Semler Scientific subsidiary's early disease detection products, which is expected to drive innovation and growth in the healthcare technology sector.
- Management Changes: Eric Semler joins Strive's board as an independent member, while Joe Burnett takes on the role of VP of Bitcoin Strategy, bringing extensive industry experience that will support the company's strategic development in both Bitcoin and medical devices.
- Asset Management Expansion: Since launching its first ETF in August 2022, Strive Asset Management has grown to manage over $2 billion in assets, and the acquisition of Semler Scientific is anticipated to further enhance its competitiveness and market share in Bitcoin asset management.
See More
Altimmune Inc Receives FDA Breakthrough Therapy Designation for Pemvidutide, Shares Surge 23.6%
- FDA Certification Impact: Altimmune Inc's Pemvidutide received FDA Breakthrough Therapy Designation, leading to a 23.6% surge in shares to $4.34 on Monday, indicating strong market confidence in its potential efficacy and possibly accelerating its path to market.
- Clinical Progress: GH Research PLC's GH001 lifted from FDA clinical hold saw shares rise 33.8% to $17.72, reflecting significant advancements in drug development that are expected to enhance its competitive position in the market.
- Executive Change: Rayonier Advanced Materials Inc appointed Scott M. Sutton as the new CEO, resulting in a 14.1% increase in shares to $6.68, suggesting that this leadership change could bring new strategic directions and growth opportunities for the company.
- Market Rebound: The overall market showed strong performance with the S&P 500 index rising, reflecting investor optimism about economic recovery, which may drive more capital inflows into the stock market.
See More
Strategy Reports Q4 Revenue Beat, Stock Futures Lower
- Revenue Beat: Strategy reported fourth-quarter revenue of $122.99 million after Thursday's close, surpassing analyst expectations of $118.48 million, indicating strong market performance that may attract more investor interest.
- Earnings Growth: The company posted adjusted earnings of $16.37 per share, exceeding analyst estimates of $10.96 per share, demonstrating significant improvement in profitability that could lay the groundwork for future growth.
- Stock Price Decline: Despite the revenue and earnings beats, Strategy's stock dipped 4.8% to $128.36 in pre-market trading, reflecting market concerns about the overall economic environment, which may impact investor confidence.
- Market Trends: U.S. stock futures were lower, with Nasdaq 100 futures falling around 100 points, indicating cautious market sentiment that could pressure tech stocks and influence overall investment strategies.
See More
Strive (ASST) Prices 1.32M Shares of Series A Preferred Stock at $90 Each
- Preferred Stock Offering: Strive announced the pricing of 1.32 million shares of its variable rate Series A perpetual preferred stock at $90 per share, providing significant funding support and enhancing its capital structure.
- Follow-On Offering Plans: The company plans a $150 million follow-on offering, reflecting a proactive response to market demand and aiding in the expansion of its capital base for future growth.
- Settlement Arrangement: The preferred stock offering is scheduled to settle on January 27, 2026, indicating the company's active engagement in capital markets and strategic planning for future financing.
- Convertible Note Exchange: Strive also intends to enter into privately negotiated exchange agreements with Semler convertible note holders for $90 million, expected to result in the issuance of approximately 930,000 new shares of SATA stock, further optimizing its capital structure.
See More
Strive (SATA) Plans $150 Million Follow-On Offering of Preferred Stock
- Offering Plan: Strive (SATA) plans a $150 million follow-on offering of its Variable Rate Series A Perpetual Preferred Stock, with implementation contingent on market conditions, aimed at optimizing its capital structure and enhancing financial flexibility.
- Use of Proceeds: The net proceeds from this offering will be used alongside cash on hand to repay or repurchase outstanding convertible notes and other borrowings at its wholly owned subsidiary Semler Scientific, as well as for bitcoin-related investments, working capital, and general corporate purposes, indicating the company's focus on diversified investments.
- Debt Restructuring Negotiations: Strive is also negotiating potential exchanges of some outstanding convertible notes for preferred shares, which could reduce the offering size, although such exchanges would not generate cash proceeds, reflecting the company's flexible strategy in optimizing its capital structure.
- Market Reaction: Following the announcement of the offering, Strive's stock price fell 2.74% in after-hours trading to $0.8679, indicating a cautious market response to the offering plan, which may impact investor confidence.
See More
Strive, Inc. Completes Semler Acquisition, Stock Declines
- Bitcoin Holdings: Strive currently holds approximately 12,797.9 bitcoins, making it the 11th largest publicly traded corporate holder globally, indicating a strategic positioning in the cryptocurrency sector.
- Executive Appointment: Avik Roy has been appointed as Chief Strategy Officer, focusing on monetizing Semler Scientific's operations by expanding into early-disease detection products, aiming to enhance the company's competitiveness in the healthcare industry.
- Stock Performance: Strive's stock is trading at $0.96, which is 5.2% above its 20-day simple moving average but 56.4% below its 100-day simple moving average, reflecting a struggle to maintain long-term momentum.
- Earnings Expectations: Analysts expect Strive to report an EPS of -$0.01 on March 30, 2026, an improvement from -$0.21 year-over-year, with projected revenue of $1.80 million, indicating potential for future growth.
See More
Strive, Inc. Completes Semler Scientific Acquisition, Holds 12,797.9 Bitcoin
- Bitcoin Holdings Increase: Following the acquisition of Semler Scientific, Strive now holds approximately 12,797.9 bitcoins, making it the 11th largest public corporate holder globally, thereby enhancing its market position in the digital asset space.
- Strategic Executive Appointment: Avik Roy has been appointed as Chief Strategy Officer, focusing on monetizing the Semler Scientific subsidiary's early disease detection products, which is expected to drive innovation and growth in the healthcare technology sector.
- Management Changes: Eric Semler joins Strive's board as an independent member, while Joe Burnett takes on the role of VP of Bitcoin Strategy, bringing extensive industry experience that will support the company's strategic development in both Bitcoin and medical devices.
- Asset Management Expansion: Since launching its first ETF in August 2022, Strive Asset Management has grown to manage over $2 billion in assets, and the acquisition of Semler Scientific is anticipated to further enhance its competitiveness and market share in Bitcoin asset management.
See More
Altimmune Inc Receives FDA Breakthrough Therapy Designation for Pemvidutide, Shares Surge 23.6%
- FDA Certification Impact: Altimmune Inc's Pemvidutide received FDA Breakthrough Therapy Designation, leading to a 23.6% surge in shares to $4.34 on Monday, indicating strong market confidence in its potential efficacy and possibly accelerating its path to market.
- Clinical Progress: GH Research PLC's GH001 lifted from FDA clinical hold saw shares rise 33.8% to $17.72, reflecting significant advancements in drug development that are expected to enhance its competitive position in the market.
- Executive Change: Rayonier Advanced Materials Inc appointed Scott M. Sutton as the new CEO, resulting in a 14.1% increase in shares to $6.68, suggesting that this leadership change could bring new strategic directions and growth opportunities for the company.
- Market Rebound: The overall market showed strong performance with the S&P 500 index rising, reflecting investor optimism about economic recovery, which may drive more capital inflows into the stock market.
See More
